SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-011278
Filing Date
2024-01-19
Accepted
2024-01-19 16:31:00
Documents
12
Period of Report
2024-01-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d701085d8k.htm   iXBRL 8-K 24485
  Complete submission text file 0001193125-24-011278.txt   145803

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA alny-20240112.xsd EX-101.SCH 2850
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE alny-20240112_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alny-20240112_pre.xml EX-101.PRE 11261
6 EXTRACTED XBRL INSTANCE DOCUMENT d701085d8k_htm.xml XML 3434
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

IRS No.: 770602661 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36407 | Film No.: 24546012
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)